Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Cullinan Oncology, Inc. (CGEM) reported significant updates and financial results for Q3 2021. The company’s cash and investments totaled $445.4 million, supporting its clinical pipeline. The Phase 1/2a trial for CLN-081 in advanced NSCLC is progressing, with a clinical update expected in Q4 2021. Additionally, Cullinan plans to initiate clinical trials for CLN-619 and CLN-049 by year's end. R&D expenses rose to $12.7 million, while G&A expenses increased to $5.7 million, leading to a net loss of $18.3 million.
- Strong cash position of $445.4 million to fund clinical trials.
- Advancement of multiple clinical trials, including CLN-081, CLN-619, and CLN-049.
- Increased R&D expenses of $12.7 million compared to previous quarters.
- Net loss of $18.3 million for the third quarter, up from $16.4 million in Q2.
Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021
Cullinan MICA and Cullinan Florentine programs to advance into clinical trials by year end 2021
Strong balance sheet with cash and investments of
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2021.
“Our organization has made great progress advancing our pipeline of novel, targeted oncology programs across multiple modalities, positioning us to deliver on our 2021 milestones,” stated Nadim Ahmed, Chief Executive Officer of Cullinan Oncology. “We are encouraged by the clinical profile emerging from our lead program, Pearl (CLN-081), in heavily pretreated advanced NSCLC patients that harbor EGFR exon 20 insertion mutations and are looking forward to providing a clinical update from our ongoing Phase 1/2a trial later this quarter. We are also excited to advance Cullinan MICA and Cullinan Florentine into clinical trials this quarter. With our evolution into a late stage oncology company, we are utilizing our significant financial resources of over
Portfolio Highlights
- Cullinan Pearl: Continued advancing the Phase 1/2a trial evaluating CLN-081 in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 mutations who progressed on platinum-based chemotherapy. Cullinan intends to provide a clinical update on Pearl in the fourth quarter of 2021. The update will include 67 patients enrolled across all five dose cohorts, including 36 response-evaluable patients at the 100 mg BID dose cohort.
- Cullinan MICA: CLN-619 is a monoclonal antibody designed to promote an antitumor response by engaging both natural killer (NK) and T cells through the MICA/B–NKG2D axis, with broad therapeutic potential across multiple cancer indications. Cullinan remains on track to open for enrollment a first-in-human clinical trial evaluating CLN-619 in patients with advanced solid tumors in the fourth quarter of 2021. The trial will include a dose escalation cohort followed by dose expansion cohorts as a monotherapy and in combination with checkpoint inhibitor therapy. Cullinan expects CLN-619 to be the first therapeutic candidate targeting MICA/B to enter clinical trials.
- Cullinan Florentine: CLN-049 is a bispecific antibody designed to simultaneously bind to FLT3 on target leukemic cells and to CD3 on T cells, triggering T cells to kill the targeted cancer cells. Cullinan remains on track to open for enrollment a first-in-human clinical trial evaluating CLN-049 in patients with relapsed/refractory acute myeloid leukemia in the fourth quarter of 2021.
- Cullinan Amber: CLN-617 is a collagen binding fusion protein that contains both IL-12 and IL-2 in a single molecule. CLN-617 has now advanced to the IND-enabling phase. Cullinan will present preclinical data at the upcoming Society for Immunotherapy of Cancer annual meeting.
- Cullinan NexGem: CLN-978 is a half-life extended T cell engaging antibody construct designed to simultaneously engage CD19 and CD3. Cullinan continues to advance CLN-978 through IND-enabling development.
Third Quarter 2021 Financial Results
- Cash Position: Cash, cash equivalents and investments were
$445.4 million as of September 30, 2021. - R&D Expenses: Research and development (R&D) expenses were
$12.7 million for the third quarter of 2021, compared to$11.8 million for the second quarter of 2021. The increase in R&D expenses is primarily related to expanded clinical and CMC activity associated with portfolio advancement. - G&A Expenses: General and administrative (G&A) expenses were
$5.7 million for the third quarter of 2021, compared to$4.8 million for the second quarter of 2021. The change in G&A expenses is primarily related to increased professional services fees and equity-based compensation expenses. - Net Loss: The Company’s net loss (before items attributable to noncontrolling interest) was
$18.3 million for the third quarter of 2021, compared to$16.4 million for the second quarter of 2021.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company with a diversified pipeline of targeted therapeutic candidates across multiple modalities. The Company’s strategy is to focus on advanced stage assets with novel technology platforms and differentiated mechanisms, developed through both internal discovery and external collaboration. Learn more about Cullinan at www.cullinanoncology.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan’s beliefs and expectations regarding our preclinical and clinical development plans, clinical trial designs, clinical and therapeutic potential, and strategy of our product candidates, including but not limited to: the timing and success of our planned preclinical and clinical development of our programs, including for CLN-081, CLN-619, and CLN-049, and the timing and success of our planned regulatory submissions; our expectations and beliefs around the safety and activity of CLN-081 in our Phase 1/2a trial in patients with NSCLC harboring EGFRex20ins mutations that have had at least one prior treatment; our ability to evaluate strategic opportunities to accelerate development timelines; the presentation of additional data at upcoming scientific conferences in 2021; our ability to optimize the impact of our collaborations and license agreements with external parties; our ability to continue our growth; and our expectations regarding our use of capital. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our product candidates; risks related to the impact of COVID-19 affecting countries or regions in which we have operations or do business, including potential negative impacts on our employees, customers, supply chain and production as well as global economies and financial markets; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission (SEC), including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.
Cullinan Oncology, Inc.
Consolidated Balance Sheets (Unaudited)
(in thousands, except shares and per share amounts)
| December 31, 2020 | September 30, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 168,198 | $ | 88,105 | ||||
| Short-term investments | 42,008 | 232,939 | ||||||
| Prepaid expenses and other current assets | 2,072 | 7,794 | ||||||
| Total current assets | 212,278 | 328,838 | ||||||
| Property and equipment, net | 130 | 89 | ||||||
| Other assets | 2,300 | 147 | ||||||
| Long-term investments | — | 124,330 | ||||||
| Total assets | $ | 214,708 | $ | 453,404 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 9,679 | $ | 2,024 | ||||
| Accrued expenses and other current liabilities | 4,641 | 5,839 | ||||||
| Total current liabilities | 14,320 | 7,863 | ||||||
| Long-term liabilities: | ||||||||
| Deferred rent | 74 | 67 | ||||||
| Total liabilities | 14,394 | 7,930 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, | 3 | 4 | ||||||
| Additional paid-in capital | 292,348 | 569,835 | ||||||
| Accumulated other comprehensive loss | (2 | ) | (58 | ) | ||||
| Accumulated deficit | (93,339 | ) | (126,395 | ) | ||||
| Total Cullinan stockholders' equity | 199,010 | 443,386 | ||||||
| Noncontrolling interests | 1,304 | 2,088 | ||||||
| Total stockholders' equity | 200,314 | 445,474 | ||||||
| Total liabilities and stockholders' equity | $ | 214,708 | $ | 453,404 | ||||
Cullinan Oncology, Inc.
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except shares and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2020 | 2021 | 2020 | 2021 | |||||||||||||
| License revenue | $ | — | $ | — | $ | — | $ | 18,943 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 9,913 | 12,680 | 26,582 | 36,873 | ||||||||||||
| General and administrative | 1,586 | 5,695 | 4,580 | 15,677 | ||||||||||||
| Total operating expenses | 11,499 | 18,375 | 31,162 | 52,550 | ||||||||||||
| Loss from operations | (11,499 | ) | (18,375 | ) | (31,162 | ) | (33,607 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 185 | 118 | 809 | 340 | ||||||||||||
| Other income (expense), net | — | (2 | ) | 1 | (12 | ) | ||||||||||
| Net loss | (11,314 | ) | (18,259 | ) | (30,352 | ) | (33,279 | ) | ||||||||
| Net loss attributable to noncontrolling interest | (1,456 | ) | (909 | ) | (6,899 | ) | (223 | ) | ||||||||
| Net loss attributable to common stockholders of Cullinan | $ | (9,858 | ) | $ | (17,350 | ) | $ | (23,453 | ) | $ | (33,056 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.50 | ) | $ | (0.40 | ) | $ | (1.21 | ) | $ | (0.76 | ) | ||||
| Total weighted-average shares used in computing net loss per share, basic and diluted | 19,721,992 | 43,438,861 | 19,453,479 | 43,254,230 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (11,314 | ) | $ | (18,259 | ) | $ | (30,352 | ) | $ | (33,279 | ) | ||||
| Unrealized gain/(loss) on investments | (144 | ) | 57 | 63 | (56 | ) | ||||||||||
| Comprehensive loss | (11,458 | ) | (18,202 | ) | (30,289 | ) | (33,335 | ) | ||||||||
| Comprehensive loss attributable to noncontrolling interest | (1,456 | ) | (909 | ) | (6,899 | ) | (223 | ) | ||||||||
| Comprehensive loss attributable to Cullinan | $ | (10,002 | ) | $ | (17,293 | ) | $ | (23,390 | ) | $ | (33,112 | ) | ||||
Contacts:
Investor Relations
investors@cullinanoncology.com
Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com
FAQ
What are Cullinan Oncology's financial results for Q3 2021?
What clinical trials is Cullinan Oncology planning to start?
When will Cullinan provide an update on the Pearl trial?
What are the R&D expenses for Cullinan Oncology in Q3 2021?
How does Cullinan's cash position support its operations?
